Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Boron containing doai
Reexamination Certificate
2011-03-29
2011-03-29
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Boron containing doai
C544S069000, C546S013000, C548S110000, C549S004000, C568S006000
Reexamination Certificate
active
07915236
ABSTRACT:
The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
REFERENCES:
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4537773 (1985-08-01), Shenvi
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5023236 (1991-06-01), Edgington et al.
patent: 5106948 (1992-04-01), Kinder et al.
patent: 5159060 (1992-10-01), Kinder et al.
patent: 5169841 (1992-12-01), Kleeman et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5470864 (1995-11-01), Duflos et al.
patent: 5550262 (1996-08-01), Iqbal et al.
patent: 5580486 (1996-12-01), Labeque et al.
patent: 5585390 (1996-12-01), Duflos et al.
patent: 5614649 (1997-03-01), Iqbal et al.
patent: 5658885 (1997-08-01), Lee et al.
patent: 5693617 (1997-12-01), Stein et al.
patent: 5780454 (1998-07-01), Adams et al.
patent: 5830870 (1998-11-01), Iqbal et al.
patent: 5834487 (1998-11-01), Lum et al.
patent: 5990083 (1999-11-01), Iqbal et al.
patent: 6066730 (2000-05-01), Adams et al.
patent: 6075150 (2000-06-01), Wang et al.
patent: 6083903 (2000-07-01), Adams et al.
patent: 6096778 (2000-08-01), Chatterjee et al.
patent: 6297217 (2001-10-01), Adams et al.
patent: 6310057 (2001-10-01), Chatterjee et al.
patent: 6372883 (2002-04-01), Attwood et al.
patent: 6465433 (2002-10-01), Adams et al.
patent: 6548668 (2003-04-01), Adams et al.
patent: 2001/0012854 (2001-08-01), Siman et al.
patent: 2002/0173488 (2002-11-01), Adams et al.
patent: 2002/0188100 (2002-12-01), Plamondon et al.
patent: 2003/0008828 (2003-01-01), Priestley et al.
patent: 2005/0101781 (2005-05-01), Agoulnik et al.
patent: 199 14 474 (1999-10-01), None
patent: 315574 (1989-05-01), None
patent: 354522 (1990-02-01), None
patent: 632026 (1994-06-01), None
patent: 293881 (1998-12-01), None
patent: 0 995 757 (2000-04-01), None
patent: 01166781 (2002-02-01), None
patent: WO 89/09225 (1989-10-01), None
patent: WO 91/13904 (1991-09-01), None
patent: WO 94/04653 (1994-03-01), None
patent: WO 94/17816 (1994-08-01), None
patent: WO 94/25049 (1994-11-01), None
patent: WO 94/25051 (1994-11-01), None
patent: WO 95/09634 (1995-04-01), None
patent: WO 95/09838 (1995-04-01), None
patent: WO 95/20603 (1995-08-01), None
patent: WO 95/25533 (1995-09-01), None
patent: WO 96/11697 (1996-04-01), None
patent: WO 96/12499 (1996-05-01), None
patent: WO 96/13266 (1996-05-01), None
patent: WO 96/14857 (1996-05-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/30707 (1999-06-01), None
patent: WO 00/02548 (2000-01-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 00/64467 (2000-11-01), None
patent: WO 00/64863 (2000-11-01), None
patent: WO 00/66557 (2000-11-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 01/20995 (2001-03-01), None
patent: WO 01/28579 (2001-04-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/30455 (2002-04-01), None
patent: WO 02/059130 (2002-08-01), None
patent: WO 02/059131 (2002-08-01), None
patent: WO 02/082091 (2002-10-01), None
patent: WO 02/094857 (2002-11-01), None
patent: WO 02/096933 (2002-12-01), None
patent: WO 03/015706 (2003-02-01), None
patent: WO 03/033507 (2003-04-01), None
patent: WO 03/059898 (2003-07-01), None
patent: WO 2005/016859 (2005-02-01), None
Adams et al., “Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids,”Bioorganic&Medicinal Chemistry Letters, 1998, vol. 8, Issue 4, pp. 333-338.
Aoyagi et al., “Structures and activities of protease inhibitors of microbial origin,”Proteases and Biological Control, 1975, pp. 429-454.
Attwood et al., “The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase,”Antiviral Chemistry&Chemotherapy, 1999, vol. 10, Issue 5, pp. 259-273.
Christie et al., “Alzheimer's Disease: Correlation of the Suppression of β-Amyloid Peptide Secretion From Cultured Cells With Inhibition of the Chymotrypsin-Like Activity of the Proteasome,”J. of Neurochemistry, 1999, vol. 73, Issue 1, pp. 195-204.
Dick et al., “Degradation of oxidized insulin B chain by the multiproteinase complex macropain (proteasome),”Biochemistry, Mar. 12, 1991;30(10):2725-34.
Dudson et al., “Solid Phase Synthesis of Aminoboronic Acids: Potent Inhibitors of the Hepatitis C Virus NS3 Proteinase,”Bioorganic&Medicinal Chemistry Letters, 2000, vol. 10, No. 14, pp. 1577-1579.
Evrard-Todeschi et al., “Conformations in Soluation and Bound to Bacterial Ribonsomes of Ketolides, HMR 3647 (Telithromycin) and RU 72366: A New Class of Highly Potent Antibacterials,”Bioorg. Med. Chem., Jul. 2000;8(7):1579-97.
Fenteany et al., “Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin,”Science, May 5, 1995;268(5211):726-31.
Fenteany et al., “A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line,”Proc Natl Acad Sci, Apr. 12, 1994;91(8):3358-62.
Garcia et al., “A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome,”Bioorg Med Chem Lett., May 21, 2001;11(10):1317-9.
Gardner et al., “Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells,”Biochem J., Mar. 1, 2000;346 Pt 2:447-54.
Goldberg et al., “The mechanism and functions of ATP-dependent proteases in bacterial and animal cells,”Eur J Biochem.Jan. 15, 1992;203(1-2):9-23.
Goldberg et al., “Proteolysis, proteasomes and antigen presentation,”Nature.Jun. 4, 1992;357(6377):375-9.
Iqbal et al., “Potent inhibitors of proteasome,”J Med Chem., Jun. 23, 1995;38(13):2276-7.
Iqbal et al., “Potent α-Ketocarbonyl and Boronic Ester Derived Inhibitors of Proteasome,”Bioorg. Med. Chem. Lett., 1996, vol. 6, p. 287-290.
Kettner et al., “Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids,”J Biol Chem.Dec. 25, 1984;259(24):15106-14.
Kisselev et al., “Proteasome inhibitors: from research tools to drug candidates,”Chem Biol., Aug. 2001;8(8):739-58.
Li et al., “Isolation and characterization of a novel endogenous inhibitor of the proteasome,”Biochemistry, Oct. 8, 1991;30(40):9709-15.
Matteson et al., “99% Chirally Selective Synthesis Via Pinanediol Boronic Esters: Insect Pheromones, Diols, and an Amino Alcohol,”J. Am. Chem. Soc., 1986, vol. 108, pp. 810-819.
Murakami et al., “Endogenous inhibitor of nonlysosomal high molecular weight protease and calcium-dependent protease,”Proc Natl Acad Sci., Oct. 1986;83(20):7588-92.
Nkemgu-Njinkeng et al., “Antitrypanosomal Activities of Proteasome Inhibitors,”Antimicrob. Agents Chemother., Jun. 2002;46(6):2038-40.
Orlowski et al., “The multicatalytic proteinase complex, a major extralysosomal proteolytic system,”Biochemistry, Nov. 13, 1990;29(45):10289-97.
Purandare et al., “Identification of a Potent and Rapidly Reversible Inhibitor of the 20S-Proteasome,”Bioorganic&Medicinal Chemistry Letters, 2004, pp. 1-4.
Rivett et al., “The multicatalytic proteinase of mammalian cells,”Arch Biochem Biophys., Jan. 1989;268(1):1-8.
Rivett et al., “The multicatalytic proteinase. Multiple proteolytic activities,”J. Biol Chem., Jul. 25, 1989;264(21):12215-9.
Rock et al., “Inhibitors of the proteasome block the degradation of most cell proteins and the gen
Bernardini Raffaella
Bernareggi Alberto
Cassara Paolo G.
Chatterjee Sankar
D'Arasmo Germano
Cephalon Inc.
Zucker Paul A
LandOfFree
Proteasome inhibitors and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteasome inhibitors and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteasome inhibitors and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2743423